UPDATE -- SeaSpine Announces Launch of Shoreline® Anterior Cervical Standalone System
27 September 2017 - 2:41AM
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical
technology company focused on surgical solutions for the treatment
of spinal disorders, today announced the full commercial launch of
the Shoreline Anterior Cervical Standalone (ACS) System, featuring
TruProfile™ technology.
The Shoreline ACS System is designed to deliver maximum
flexibility and modularity, offering zero- and low-profile plating
options, including two, three and four hole variations, as well as
10 and 15 degree lordotic implants. This selection provides
surgeons the ability to intraoperatively address a wide range of
anatomy, surgical situations or bone. In addition, TruProfile
technology offers a low profile plate design at 1.6mm thickness,
minimizing the profile on the anterior aspect of the spine and
minimizing cephalad caudal encroachment of adjacent segments.
“Shoreline with TruProfile has met the challenge of combining
ease of implant placement and plate fixation to allow for a more
responsive approach to specific patient requirements,” stated Dr.
James Bruffey, an orthopedic surgeon in San Diego, CA.
All Shoreline interbody implants feature proprietary
NanoMetalene surface technology designed to provide a bone-friendly
titanium surface while retaining the benefits associated with
traditional PEEK devices, such as biocompatibility, a modulus of
elasticity like bone, and excellent radiographic visibility for
post-operative imaging. NanoMetalene describes a sub-micron layer
of commercially pure titanium molecularly bonded to a PEEK implant
using a proprietary, high-energy, low-temperature process.
Unlike other titanium coating applications, this process maximizes
the implant surface area that has titanium nanotopography.
“The modular design of Shoreline with TruProfile is intended to
optimize operating room efficiency and maximize procedural
flexibility, while NanoMetalene provides the latest in surface
technology,” stated Keith Valentine, President and Chief Executive
Officer of SeaSpine. “In addition, we believe the
hyperlordotic and large footprint offerings enable surgeons to
assemble the best construct option to match patient anatomy.”
About SeaSpine SeaSpine is a global
medical technology company focused on the design, development and
commercialization of surgical solutions for the treatment of
patients suffering from spinal disorders. SeaSpine has a
comprehensive portfolio of orthobiologics and spinal implant
solutions to meet the varying combinations of products that
neurosurgeons and orthopedic spine surgeons need to perform fusion
procedures on the lumbar, thoracic and cervical spine. SeaSpine’s
orthobiologics products consist of a broad range of advanced and
traditional bone graft substitutes that are designed to improve
bone fusion rates following a wide range of orthopedic surgeries,
including spine, hip, and extremities procedures. SeaSpine’s spinal
implant portfolio consists of an extensive line of products to
facilitate spinal fusion in minimally invasive surgery (MIS),
complex spine, deformity and degenerative procedures. Expertise in
both orthobiologic sciences and spinal implant product development
allows SeaSpine to offer its surgeon customers a differentiated
portfolio and a complete solution to meet their fusion
requirements. SeaSpine currently markets its products in the United
States and in over 30 countries worldwide.
Forward-Looking StatementsSeaSpine cautions you
that statements included in this news release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements may include, but are not limited
to, statements relating to: the design and other benefits of the
Shoreline ACS System, TruProfile technology, and NanoMetalene; the
ability of the Shoreline ACS System to optimize operating room
efficiency, maximize procedural flexibility, or enable surgeons to
assemble the best construct option. Among the factors that
could cause or contribute to material differences between our
actual results and the expectations indicated by our
forward-looking statements are risks and uncertainties that
include, but are not limited to: the ability of newly launched
products to perform as designed and intended and to meet the
clinical needs of surgeons and patients; the limited clinical
experience supporting the commercial launch of new products and the
risk that such products may require substantial additional
development activities, which could introduce unexpected expense
and delay; the lack of long-term clinical data supporting the
safety and efficacy of the Company’s products; and other risks and
uncertainties more fully described in our news releases and
periodic filings with the Securities and Exchange Commission. The
Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. SeaSpine
does not intend to revise or update any forward-looking statement
set forth in this news release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
Investor Relations Contact Lynn Pieper (415)
309-5999ir@seaspine.com
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From Apr 2024 to May 2024
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From May 2023 to May 2024